Evidence map›Paper›PMID 33938745›Full record

ArticleACS sensors2021

System Modularity Chip for Analysis of Rare Targets (SMART-Chip): Liquid Biopsy Samples.

Thilanga N Pahattuge, Ian M Freed, Mateusz L Hupert, Swarnagowri Vaidyanathan, Katie Childers, Malgorzata A Witek, Kumuditha Weerakoon-Ratnayake, Daniel Park, Anup Kasi, Mazin F Al-Kasspooles and 2 more

Open access · greenAbstract read
In one paragraph

Article in ACS sensors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.International journal of molecular sciences · 2022
    Review
  13. Application of Microfluidics in Detection of Circulating Tumor Cells.Frontiers in bioengineering and biotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Thilanga N PahattugeDepartment of Chemistry, University of Kansas, 1567 Irving Hill Road, Lawrence, Kansas 66045, United States.
Ian M FreedDepartment of Chemistry, University of Kansas, 1567 Irving Hill Road, Lawrence, Kansas 66045, United States.
Mateusz L HupertBioFluidica, Inc., 1567 Irving Hill Road, Lawrence, Kansas 66045, United States.
Swarnagowri VaidyanathanCenter of BioModular Multi-scale Systems for Precision Medicine, University of Kansas, Lawrence, Kansas 66045, United States.
Katie ChildersCenter of BioModular Multi-scale Systems for Precision Medicine, University of Kansas, Lawrence, Kansas 66045, United States.
Malgorzata A WitekDepartment of Chemistry, University of Kansas, 1567 Irving Hill Road, Lawrence, Kansas 66045, United States.
Kumuditha Weerakoon-RatnayakeDepartment of Chemistry, University of Kansas, 1567 Irving Hill Road, Lawrence, Kansas 66045, United States.ORCID 0000-0002-6839-4515
Daniel ParkCenter of BioModular Multi-scale Systems for Precision Medicine, University of Kansas, Lawrence, Kansas 66045, United States.
Anup KasiDepartment of Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas 66160, United States.
Mazin F Al-KasspoolesDepartment of Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas 66160, United States.
Michael C MurphyCenter of BioModular Multi-scale Systems for Precision Medicine, University of Kansas, Lawrence, Kansas 66045, United States.ORCID 0000-0003-1108-3238
Steven A SoperDepartment of Chemistry, University of Kansas, 1567 Irving Hill Road, Lawrence, Kansas 66045, United States.ORCID 0000-0002-8292-7058
University of Kansas · USLouisiana State University · USUniversity of Kansas Medical Center · USBioFluidica (United States) · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Kalyani Pyaram, Steven Allan Soper · 2019 to 2026
$21.5M
Single-Molecule Processing: Detection and Identification of Single DNAs, RNAs, and Proteins using Immobilized Nanoscale Enzymatic Reactors (INERs) and Nanoscale ElectrophoresisP41EB020594 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sunggook Park · 2015 to 2026
$15.2M
Increased Sensitivity of Minimal Residual Disease Monitoring using Peripheral Blood in Pediatric Patients with Acute Lymphoblastic LeukemiaR33CA235597 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI AUGUST, KEITH, SOPER, STEVEN ALLAN · 2019 to 2022
$906k
NCI NIH HHS P30 CA168524NCI NIH HHS R33 CA235597NIBIB NIH HHS P41 EB020594NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

Liquid biopsies are becoming popular for managing a variety of diseases due to the minimally invasive nature of their acquisition, thus potentially providing better outcomes for patients. Circulating tumor cells (CTCs) are among the many different biomarkers secured from a liquid biopsy, and a number of efficient platforms for their isolation and enrichment from blood have been reported. However, many of these platforms require manual sample handling, which can generate difficulties when translating CTC assays into the clinic due to potential sample loss, contamination, and the need for highly specialized operators. We report a system modularity chip for the analysis of rare targets (SMART-Chip) composed of three task-specific modules that can fully automate processing of CTCs. The modules were used for affinity selection of the CTCs from peripheral blood with subsequent photorelease, simultaneous counting, and viability determinations of the CTCs and staining/imaging of the CTCs for immunophenotyping. The modules were interconnected to a fluidic motherboard populated with valves, interconnects, pneumatic control channels, and a fluidic network. The SMART-Chip components were made from thermoplastics via microreplication, which lowers the cost of production making it amenable to clinical implementation. The utility of the SMART-Chip was demonstrated by processing blood samples secured from colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) patients. We were able to affinity-select EpCAM expressing CTCs with high purity (0-3 white blood cells/mL of blood), enumerate the selected cells, determine their viability, and immunophenotype the cells. The assay could be completed in <4 h, while manual processing required >8 h.

Indexed as

Neoplastic Cells, CirculatingPancreatic NeoplasmsCell CountCell SeparationHumansLiquid Biopsyaffinity enrichmentcirculating tumor cellsimmunophenotypingimpedance sensingintegrated modular systemliquid biopsymicrofluidics

Identifiers

PMID33938745
PMCPMC8325110
OpenAlexW3158782490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.